Lite Strategy (LITS) Enterprise Value (2010 - 2026)
Lite Strategy (LITS) posted quarterly Enterprise Value of -$7.5 million for Q1 2026, up 63.2% year-over-year from -$4.6 million in Q1 2025, and up 13.86% quarter-over-quarter from -$8.8 million in Q4 2025.
Lite Strategy (LITS) Enterprise Value (2010 - 2026) Analysis & Trends
Lite Strategy's Enterprise Value history runs 17 years deep, the most recent figure standing at -$7.5 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 63.2% year-over-year to -$7.5 million; the TTM figure through Mar 2026 stood at -$7.5 million (up 63.2% YoY), while the FY2025 annual figure was -$18.0 million, up 53.03% from the prior year.
- Enterprise Value for Q1 2026 stood at -$7.5 million, up from -$8.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$7.5 million in Q1 2026, with the low at -$327.0 million in Q1 2022.
- The 5-year median for Enterprise Value is -$56.6 million (2024), against an average of -$83.6 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 98.62% in 2022, then jumped 74.95% in 2023.
- Lite Strategy's Enterprise Value stood at -$237.4 million in 2022, then surged by 74.95% to -$59.5 million in 2023, then surged by 60.15% to -$23.7 million in 2024, then surged by 63.05% to -$8.8 million in 2025, then gained by 13.86% to -$7.5 million in 2026.
- Business Quant data shows LITS's Enterprise Value at -$7.5 million in Q1 2026, -$8.8 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Lite Strategy | 33.69 Mn | 26.14 Mn | - | -7.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.54 Mn |
| Dec 31, 2025 | -8.76 Mn |
| Sep 30, 2025 | -10.11 Mn |
| Jun 30, 2025 | -18.01 Mn |
| Mar 31, 2025 | -20.50 Mn |
| Dec 31, 2024 | -23.70 Mn |
| Sep 30, 2024 | -26.95 Mn |
| Jun 30, 2024 | -38.35 Mn |
| Mar 31, 2024 | -56.57 Mn |
| Dec 31, 2023 | -59.47 Mn |
| Sep 30, 2023 | -82.17 Mn |
| Jun 30, 2023 | -100.69 Mn |
| Mar 31, 2023 | -112.01 Mn |
| Dec 31, 2022 | -237.43 Mn |
| Sep 30, 2022 | -138.37 Mn |
| Jun 30, 2022 | -153.25 Mn |
| Mar 31, 2022 | -326.97 Mn |
| Dec 31, 2021 | -185.75 Mn |
| Sep 30, 2021 | -275.39 Mn |
| Jun 30, 2021 | -153.43 Mn |